Psicumex
June 1, 2024
Andrea Herrera Solís, Jacqueline Cortés Morelos, Alejandra E. Ruiz Contreras et al.
Los enteógenos han surgido en la investigación clínica como un tratamiento alternativo para la Depresión Resistente al Tratamiento (DRT). Tienen efectos antidepresivos rápidos y duraderos, son ansiolíticos, y mitigan la ideación suicida. Además, inducen emociones positivas y provocan experiencias místicas o espirituales, atributos que pueden contribuir a su eficacia terapéutica, dada la...
Nervenheilkunde
June 1, 2024
Uwe Herwig
1 citation
ZUSAMMENFASSUNG Die menschliche Nutzung heute als psychedelisch bezeichneter Substanzen erfolgt bereits seit Jahrtausenden. Die wissenschaftliche Untersuchung, zunächst pharmakologisch, später psychiatrisch, setzte ab Ende des 19. Jahrhunderts ein. Die ersten Überlegungen zur klinischen Anwendung insbesondere zur Unterstützung von Psychotherapien wurden ab Mitte des 20. Jahrhunderts umgesetzt...
Journal of Psychosocial Nursing and Mental Health Services
June 1, 2024
Patty R Wilson, Emma Jagasia, Jennifer Lee et al.
1 citation
Poly-victimization is often reported by formerly incarcerated women and leads to physical and mental health problems that interfere with daily functioning, sustained employment, and housing stability. Although reentry programs exist, few focus on the physical and emotional impact of multiple traumas. Passport to Freedom (P2F), a woman-centered, trauma-informed reentry program, was developed to...
Canadian Journal on Aging
June 1, 2024
Sandrine Kalenzaga, David Clarys
La maladie d'Alzheimer se manifeste par des troubles de la mémoire et un déclin cognitif plus général, le plus souvent associés à des troubles de l'humeur et du comportement. Les traitements médicamenteux ayant une efficacité assez modeste, il apparaît nécessaire de leur associer une prise en charge non pharmacologique. La méditation de pleine conscience, qui a des effets bénéfiques sur le...
AIDS and behavior
June 1, 2024
Judith T. Moskowitz, Brijesh Sharma, Shireen Javandel et al.
2 citations
The growing number of people aging with HIV represents a group vulnerable to the symptom burdens of HIV-associated neurocognitive disorder (HAND). Among younger groups, Mindfulness-Based Stress Reduction (MBSR) has been shown to help people living with HIV manage HIV-related and other life stress, and although there is some theoretical and empirical evidence that it may be effective among those...
Obstetrics and gynecology clinics of North America
June 1, 2024
Lori A Brotto, Melanie Altas
5 citations
Mindfulness is defined as present-moment, nonjudgmental awareness. By reducing self-criticism, and depression, and increasing self-compassion, attention, and interoceptive awareness, mindfulness has been found across a variety of systematic reviews and meta-analyses to significantly improve sexual desire, sexual pain, and sex-related distress. It helps individuals connect with their bodies,...
CHEST critical care
June 1, 2024
Christopher E Cox, John A Gallis, Maren K Olsen et al.
3 citations
Psychological distress symptoms are present and persistent among many patients who survive a critical illness like COVID-19. Could a self-directed mobile app-delivered mindfulness intervention be feasibly and rapidly implemented within a clinical trials network to reduce distress symptoms? A randomized clinical trial was conducted between January 2021 and May 2022 at 29 US sites and included...
Pharmacological Reports
June 1, 2024
Agnieszka Pałucha-Poniewiera, Anna Rafało-Ulińska, Michal Santocki et al.
8 citations
Partial negative allosteric modulators (NAM) of the metabotropic glutamate 5 (mGlu5) receptor are an excellent alternative to full antagonists and NAMs because they retain therapeutic effects and have a much broader therapeutic window. Here, we investigated whether partial mGlu5 NAM, 2-(2-(3-methoxyphenyl)ethynyl)-5-methylpyridine (M-5MPEP), induced a fast and sustained antidepressant-like...
Psychedelic Medicine
June 1, 2024
Abshir S Adam, Kayleigh S. Lamalfa, Yasaman Razavi et al.
6 citations
Frontline antidepressants such as selective serotonin reuptake inhibitors (SSRIs) leave many patients with unmet treatment needs. Moreover, even when SSRIs reduce depressive symptoms, anhedonia, the loss of pleasure to previously rewarding activities, often remains unabated. This state of affairs is disheartening and calls for the development of medications to more directly treat anhedonia. The...
British Journal of Pharmacology
June 1, 2024
Isabel Werle, Laura M M Nascimento, Aymee L A Dos Santos et al.
21 citations
Ayahuasca (AYA) is a botanical psychedelic with promising results in observational and small clinical trials for depression, trauma and drug use disorders. Its psychoactive effects primarily stem from N,N-dimethyltryptamine (DMT). However, there is a lack of research on how and where AYA acts in the brain. This study addressed these questions by examining the extinction of aversive memories in...